| Identification | Back Directory | [Name]
N-[[1-(2-Cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-3-quinolinyl]carbonyl]glycine | [CAS]
931399-19-8 | [Synonyms]
GSK360A
N-[[1-(2-Cyclopropylethyl)-6-fluoro-1,2-dihydro-4-hydroxy-2-oxo-3-quinolinyl]carbonyl]glycine
N-[[1-(2-Cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-3-quinolinyl]carbonyl]glycine
Glycine, N-[[1-(2-cyclopropylethyl)-6-fluoro-1,2-dihydro-4-hydroxy-2-oxo-3-quinolinyl]carbonyl]- | [Molecular Formula]
C17H17FN2O5 | [MDL Number]
MFCD27977959 | [MOL File]
931399-19-8.mol | [Molecular Weight]
348.326 |
| Chemical Properties | Back Directory | [Melting point ]
194-198°C (dec.) | [storage temp. ]
2-8°C | [solubility ]
Acetone (Slightly, Heated), DMSO (Slightly), Methanol (Slightly) | [form ]
powder | [color ]
white to beige | [InChI]
1S/C17H17FN2O5/c18-10-3-4-12-11(7-10)15(23)14(16(24)19-8-13(21)22)17(25)20(12)6-5-9-1-2-9/h3-4,7,9,23H,1-2,5-6,8H2,(H,19,24)(H,21,22) | [InChIKey]
TYHRZQVUPPODPT-UHFFFAOYSA-N | [SMILES]
OC(C1=C(N2CCC3CC3)C=CC(F)=C1)=C(C(NCC(O)=O)=O)C2=O |
| Hazard Information | Back Directory | [Chemical Properties]
Beige Solid | [Uses]
GSK360A orally active HIF-PHD inhibitor. GSK360A exerts systemic and local effects by stabilizing HIF-1α signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These findings suggest that GSK360A may be suitable for the treatment of post-MI remodeling and heart failure. | [in vivo]
GSK360A (30 mg/kg i.g.) improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction[1]. | Animal Model: | male Lewis rats with ventricular dysfunction model[1] | | Dosage: | 30 mg/kg | | Administration: | oral gavage | | Result: | Increased circulating levels of erythropoietin and hemoglobin and hemoxygenase-1 expression in the heart and skeletal muscle of male rats. |
|
|
|